This week’s Telltales Podcast moves from geopolitics to technology to healthcare, connecting the latest market headlines back to cash flow, capital allocation, and competitive advantage. Mike, Jason, and Hunt discuss how energy risk, AI spending, and pharma dealmaking could shape investors’ thinking in the months ahead.
[00:00] Opening and memo overview
Mike opens the episode by framing the discussion around energy, technology, and healthcare, with references to the Cash Flow Memo and the weekly exhibits on government finances, natural gas, and oil.
[00:20] Iran, oil risk, and Exhibit C
Hunt lays out his current view on Iran, the Strait of Hormuz, and why geopolitical risk may keep oil prices supported rather than sending them back toward much lower levels.
[03:58] Exhibit A and the macro backdrop
The conversation shifts briefly to the dollar, defense spending, and how fiscal developments could affect the broader economic picture.
[05:03] Ceasefire timing and what to watch next
Mike and Jason discuss the significance of the April 6 date, the uncertainty around negotiations, and how public reporting can differ sharply from realities on the ground.
[06:32] Helium shortages and second-order inflation effects
The hosts revisit helium after recent supply disruptions, highlighting how conflict can ripple far beyond oil into industrial gases and other inflation-sensitive inputs.
[10:13] Middle East realignment and the long-term oil outlook
Jason and Hunt explore the bigger strategic picture, including regional cooperation, Saudi-Israel normalization, and what a more stable or less stable Middle East could mean for energy markets.
[18:38] Artemis II, NASA contractors, and the economics of launch
The episode turns to space, where the hosts compare legacy aerospace contractors with SpaceX and debate what the future of launch economics and government contracts might look like.
[21:12] Apple at 50: low capex, AI, and the future of Siri
Apple’s anniversary sparks a deeper debate on whether the company is prudently waiting on AI or risking a slow erosion of its moat by underinvesting in next-generation infrastructure and products.
[24:00] The Intel comparison and platform risk
Mike argues that Apple could face an Intel-like problem if financial discipline overtakes product ambition, especially as outside AI providers gain leverage over the user experience.
[28:00] OpenAI, suppliers, and bargaining power
The hosts examine how AI could reshape platform economics, with Apple potentially becoming more dependent on third-party model providers and losing some of its traditional control.
[30:15] Healthcare M&A and Eli Lilly’s latest push
Jason closes with healthcare news, including fresh pharma dealmaking and Eli Lilly’s move into an oral weight-loss treatment, with implications for manufacturing, pricing, and competition.
[31:24] Why Lilly looks so strong
The team discusses why Lilly continues to stand out, from product execution to strategic positioning, and tees up a deeper dive for a future episode.
Thanks for listening to Telltales. Subscribe for weekly discussions on investing, cash flow, and company analysis, and check out the Cash Flow Memo for the financial exhibits and company updates that accompany each episode.
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
